Genomic Health to Present at the Canaccord Genuity 33rd Annual Growth Conference

    Genomic Health to Present at the Canaccord Genuity 33rd Annual Growth

PR Newswire

REDWOOD CITY, Calif., Aug. 7, 2013

REDWOOD CITY, Calif., Aug. 7, 2013 /PRNewswire/ --Genomic Health, Inc.
(Nasdaq: GHDX) today announced that members of its management team will
present at the Canaccord Genuity 33^rd Annual Growth Conference in Boston on
Wednesday, August 14 at 2:00 p.m. Eastern Time (ET).


To access the live and subsequently archived webcast of the presentation,
visit the Investor Relations section of Genomic Health's website at Please connect to the website at least 15
minutes prior to the beginning of the presentation to allow for any necessary
software downloads. An archived replay will be available for three months
beginning 24 hours after the live presentation.

About Genomic Health

Genomic Health, Inc. (NASDAQ: GHDX) is a global healthcare company that
provides actionable genomic information to personalize cancer treatment
decisions. The company's lead product, the Oncotype DX® breast cancer test,
has been shown to predict the likelihood of chemotherapy benefit as well as
recurrence in invasive breast cancer and has been shown to predict the
likelihood of recurrence in ductal carcinoma in situ (DCIS). In addition to
this widely adopted test, Genomic Health provides the Oncotype DX colon cancer
test, the first multi-gene expression test developed for the assessment of
risk of recurrence in patients with stage II and stage III disease, and the
Oncotype DX prostate cancer test, which predicts disease aggressiveness in men
with low risk disease. As of June 30, 2013, more than 19,000 physicians in
over 70 countries had ordered more than 375,000 Oncotype DX tests. Genomic
Health has a robust pipeline focused on developing tests to further optimize
the treatment of breast, colon and prostate cancers, as well as the treatment
of renal cancer. The company is based in Redwood City, California with
European headquarters in Geneva, Switzerland. For more information, please
visit, and follow the company on Twitter:
@GenomicHealth. To learn more about Oncotype DX tests, visit:, and 

This press release contains forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995, including statements
relating to the attributes and focus of the company's product pipeline; the
applicability of clinical study results to actual outcomes; the potential
economic benefits associated with the company's tests; the ability of the
company to develop additional tests in the future; the demand for the
company's tests; the ability of any potential tests the company may develop to
optimize cancer treatment and the Company's ability to launch new tests in new
markets and expand internationally. Forward-looking statements are subject to
risks and uncertainties that could cause actual results to differ materially,
and reported results should not be considered as an indication of future
performance. These risks and uncertainties include, but are not limited to:
the risks and uncertainties associated with the regulation of the company's
tests; the results of clinical studies; the applicability of clinical study
results to actual outcomes; our ability to develop and commercialize new
tests; unanticipated costs or delays in research and development efforts; our
ability to obtain capital when needed and the other risks set forth in the
company's filings with the Securities and Exchange Commission, including the
risks set forth in the company's Quarterly Report on Form 10-Q for the period
ended June 30, 2013. These forward-looking statements speak only as of the
date hereof. Genomic Health disclaims any obligation to update these
forward-looking statements.

NOTE: The Genomic Health logo, Oncotype, Oncotype DX, Recurrence Score, and
DCIS Score are trademarks or registered trademarks of Genomic Health, Inc. All
other trademarks and service marks are the property of their respective

SOURCE Genomic Health, Inc.

Contact: Investors: Dean Schorno, Genomic Health, 650-569-2281,; Media: Emily Faucette, Genomic Health,
Press spacebar to pause and continue. Press esc to stop.